论文部分内容阅读
140例 IgA 肾病患者自肾活检后随访6～72个月(平均21个月),其中25例(17.9%)发展至慢性肾功能不全,4例(2.9%)进入终末期肾衰。本文资料表明,激素治疗可减少 IgA 肾病患者的尿蛋白量,改善低蛋白血症,但不能改善其肾功能。临床上呈反复发作性肉眼血尿者预后良好。多因素分析结果表明,提示预后不良的因素有:重度蛋白尿、高血压,肾小球硬化(特别是节段性硬化)、间质纤维化、新月体形成,以及在肾小球内伴随有 IgG 和 IgM 沉积者。
One hundred and forty patients with IgA nephropathy were followed up for 6 to 72 months (mean 21 months) after biopsy, with 25 (17.9%) developing chronic renal insufficiency and 4 (2.9%) entering end-stage renal failure. This data shows that hormone therapy can reduce urinary protein in patients with IgA nephropathy to improve hypoproteinemia, but can not improve their renal function. The clinical recurrence of gross hematuria patients with good prognosis. Multivariate analysis showed that the factors that suggested the poor prognosis were severe proteinuria, hypertension, glomerulosclerosis (especially segmental sclerosis), interstitial fibrosis, crescent formation, and glomerular concomitant There are IgG and IgM depositors.